Compare Direxion Daily CSI China Internet Bull 2X Shares (CWEB) vs Cassava Sciences Inc (FLNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Direxion Daily CSI China Internet Bull 2X Shares vs Cassava Sciences Inc — how do they compare? Direxion Daily CSI China Internet Bull 2X Shares trades at $24.55, while Cassava Sciences Inc trades at $0.97 (market cap $47.75M). The key difference: Direxion Daily CSI China Internet Bull 2X Shares is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals.
| CWEB | FLNA | |
|---|---|---|
Sector | Leveraged / Inverse | Health |
52-Week High | $60.13 | $4.64 |
52-Week Low | $17.70 | $0.87 |
Market Cap | — | $47.75M |
Enterprise Value | — | -$34.93M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CWEB trades at $25.53, up 1.67% today, with a bullish technical signal from moving averages. The stock shows strong momentum indicators but an overbought short-term RSI. A dividend of $0.09 is scheduled for June 2026, reflecting potential income return. Recent news highlights renewed interest in China growth stocks, which may benefit CWEB's positioning.
The outlook for CWEB is cautiously optimistic, driven by positive technical trends and sector sentiment. Key risks include reliance on China market dynamics and potential volatility. Investment opportunity lies in growth stock resurgence, but investors must weigh macroeconomic and regulatory uncertainties in the region.
FLNA trades at $0.995, up 3.75% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported three consecutive quarterly earnings beats, with Q2 2026 EPS of -$0.18 beating expectations of -$0.225. Financials show negative cash flows and profitability, with ROE at -55.79% and net income of -$90.97M in 2025. Analyst consensus is strongly positive with 8 buy ratings out of 12.
Despite operational losses, FLNA's consistent earnings beats and strong analyst support suggest potential upside if clinical developments progress. Key risks include sustained cash burn, lack of revenue, and dependence on successful drug trials for Tuberous Sclerosis Complex. The stock remains speculative with high volatility expected.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Direxion Daily CSI China Internet Bull 2X Shares
CWEB is a leveraged ETF that seeks to provide two times (2x) the daily performance of the CSI China Internet Index. It offers magnified exposure to top Chinese internet companies listed on US and Hong Kong exchanges.
Read more on CWEB →About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →
